-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：SHOP第一季營收成長34%至31.7億美元，超出我們先前31%的預期，也高於公司本身給出的30%左右的成長率預期。其中，商家解決方案營收飆升39%至24.2億美元。商品交易總額（GMV）首次突破1,000億美元大關，達到1,007億美元（成長35%），這是一個重要的里程碑，凸顯了平台持續普及和商家參與度的提升。 SHOP展現了強勁的營運槓桿效應，儘管持續投資於人工智慧和平台擴張，其營業收入仍增長88%至3.82億美元，這反映了公司嚴格的成本控制。 SHOP預計第二季營收成長率將接近50%，較第一季的34%有所放緩，但與市場普遍預期的27%基本持平。由於公司持續投資於平台能力和人工智慧基礎設施，預計自由現金流利潤率將維持在15%左右。 SHOP第一季末持有57億美元現金且無負債，為其成長計畫提供了靈活性。我們注意到，由於去年同期基數較高，成長放緩並不令人意外。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN